Analysis of Scientific Productivities on the Three Most Famous Outbreaks of Betacoronavirus Genus: SARS, MERS and COVID-19

Öz

Aim: The 21st Century has already witnessed three outbreaks caused by the same family of coronaviruses, the Severe Acute Respiratory Syndrome (SARS), the Middle East Respiratory Syndrome (MERS) and recently, The Noval Coronavirus Disease 2019 (COVID-19). The main aim of this study is to analyze the overall scientific publications indexed in Science Citation Index Expanded (SCI-E) about these three outbreaks. And the secondary aim is to compare first scientific reactions to SARS, MERS and COVID-19 outbreaks in their early phases by using the dates of first 4 months of them. Material and Method: Web of Science (WoS) software was used for the search and the analysis. Allscientific papers, included in SCI-E, related with each outbreaks of SARS, MERS and COVID-19 from 1980 to April15.2020, were searched and analyzed by using the terms of “SARS”, “SARS-CoV” and “Severe Acute Respiratory Syndrome” for SARS; “MERS”, “MERS-CoV”, “HCoV-EMC” and “Middle East Respiratory Disease” for MERS and “COVID-19”, “2019-n-CoV”, “SARS-CoV-2”, “Coronavirus disease 19” and “2019 novel coronavirus” for COVID-19 in the topic section of the software. Results: Overall; 3690, 1517 and 730 papers, indexed by SCI-E, were found related to SARS, MERS and COVID-19 respectively. The biggest contribution for publications was from People’s Republic of China (PRC) for SARS and COVID-19 and was from The United States of America (USA) for MERS. Conclusion: In this study, it was revealed that scientific contribution to COVID-19 is faster and greatful then SARS and MERS in the early phase of the outbreak. But the pandemic potential of betacoronaviruses, especially SARS-CoV-2, remains a threat for public health globally. Therefore further research into the pathogenesis of these infections in order to find appropriate targets for treatment is imperative.

Anahtar Kelimeler

• SARS
• MERS
• COVID-19
• SARS-CoV; MERS-CoV; HCoV-EMC; SARS-CoV2

En Ünlü Üç Betakoronavirüs Salgınıyla İlgili Bilimsel Verimlilik Analizi: SARS, MERS ve COVID-19

Öz

Amaç: 21. yüzyıl, aynı koronavirüs ailesinin neden olduğu üç salgına, Şiddetli Akut Solunum Sendromu (SARS), Orta Doğu Solunum Sendromu (MERS) ve yakın zamanda Noval Koronavirüs Hastalığı 2019’un (COVID-19) tanık olmuştur. Bu çalışmanın amacı, bu üç salgın ile ilgili, Science Citation Index Expanded (SCI-E) dergilerde indekslenen genel bilimsel yayınları analiz etmektir. İkincil amacı ise SARS, MERS ve COVID-19 salgınlarına yönelik ilk bilimsel reaksiyonları erken evrelerinde, ilk 4 aylık süreçlerinde, karşılaştırmaktır. Materyal ve Metot: Arama ve analiz için ISI-Web of Knowledge- Web of Science (WoS) yazılımı kullanılmıştır. 1975’ten 15 Nisan 2020’ye kadar SARS, MERS ve COVID-19 salgını ile ilgili SCI-E indexlenen tüm bilimsel makaleler Şiddetli Akut Solunum Sendromu (SARS) için “SARS”, “SARS-CoV” ve “Şiddetli Akut Solunum Sendromu” terimleri kullanılarak; Orta Doğu Solunum Sendromu (MERS) için “MERS”, “MERS-CoV”, “HCoV-EMC” ve “Orta Doğu Solunum Sendromu” terimleri kullanılarak ve COVID-19 için “COVID-19”, “2019-n-CoV”, “SARS-CoV-2”, “Koronavirüs hastalığı 19” ve “2019 yeni koronavirüs” erimleri kullanılarak arştırma yapıldı. Bulgular: SCI-E tarafından indekslenen 3690 yayın SARS ile, 1517 yayın MERS ile ve 730 yayın COVID-19 ile ilgili bulunmuştur. Yayınlara en büyük katkı, SARS ve COVID-19 için Çin Halk Cumhuriyeti’nden (PRC); MERS için Amerika Birleşik Devletlerindendir (ABD). Sonuç: Bu çalışma ile, COVID-19’a bilimsel katkının salgının erken evresindeki SARS ve MERS’den daha hızlı ve daha büyük olduğunu gösterdik. Ancak, HCoV’lerin, özellikle SARS-CoV-2’nin pandemik potansiyeli, küresel olarak halk sağlığı için bir tehdit olmaya devam etmektedir. Bu nedenle, tedavi için uygun hedefleri bulmak için HCoV enfeksiyonlarının patogenezine yönelik daha fazla araştırma yapılması zorunludur.

Anahtar Kelimeler

• SARS
• MERS
• COVID-19
• SARS-CoV; MERS-CoV; HCoV-EMC; SARS-CoV2

Kaynakça

1. 1. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS. recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14(8):523–34.
2. 2. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, Trilling M, Lu M, Dittmer U, Yang D. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020;92(5):491–494.
3. 3. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses 2019;11(1):59.
4. 4. Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W, Ahmed N. Novel coronavirus 2019-nCoV. prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci 2020;24(4):2012–2019
5. 5. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) and coronavirus disease-2019(COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924.
6. 6. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, Wang Y, Guo X. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARSCoV. Viruses 2020;12(2):244.
7. 7. Gao H, Yao H, Yang S, li L. From SARS to MERS. evidence and speculation. Frontiers of Medicine 2016;10(4):377–382.
8. 8. Singhal TA Review of Coronavirus Disease-2019(COVID-19). Indian J Pediatr 2020;87:281–286.

9. 9. Lee KM, Jung K. Factors Influencing the Response to Infectious Diseases: Focusing on the Case of SARS and MERS in South Korea. Int J Environ Res Public Health 2019;16(8):1432.
10. 10. Reperant LA, Osterhaus ADME. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Vaccine 2017;35(35 Pt A):4470–4474.
11. 11. Al-Tawfiq JA, Zumla A, Memish ZA. Travel implications of emerging coronaviruses: SARS and MERS-CoV. Travel Med Infect Dis 2014;12(5):422–8.
12. 12. Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and Coronaviruses. Viruses 2019;11(1):41.
13. 13. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol 2015;13:123–9.
14. 14. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23.
15. 15. Weston S, Frieman MB. COVID-19: Knowns, Unknowns, and Questions. mSphere 2020;5(2): e00203–20.
16. 16. Jiang X, Rayner S, Luo MH. Does SARS-CoV-2 has a longer incubation period than SARS and MERS? J Med Virol 2020;92(5):476–478.
17. 17. Coronavirus disease (COVID-19)Available at: www. who. int/ emergencies/diseases/novel-coronavirus-2019. Accessed:11 05 2021.
18. 18. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23(2):130–137.
19. 19. Brown C. MERS differs from SARS, say experts. CMAJ 2014;186(9): E303-E304.
20. 20. Chiu WT, Huang JS, Ho YS. Bibliometric analysis of Severe Acute Respiratory Syndrome-related resear
21. 21. Zyoud SH. Global research trends of Middle East respiratory syndrome coronavirus: a bibliometric analysis. BMC Infect Dis 2016;16:255.
22. 22. Zhu C 2018 Journal impact factor list ( JCR 2018). Technical report 2018. Avalable at: https://www. researchgate. net/ publication/323571463_2018_Journal_Impact_Factor_JCR_2018.
23. 23. Bas K, Dayangac M, Yaprak O, Yuzer Y, Tokat Y. International collaboration of Turkey in liver transplantation research: a bibliometric analysis. Transplant Proc 2011;43:3796–801.
24. 24. Bas K, Derici S, Arkan T, Yener S, Atila K. Global Practice vs. Research on Bariatric Surgery Over the Last Decade. Clin Surg 2016;1:1201.
25. 25. Haustein S, Larivière V. The Use of Bibliometrics for Assessing Research: Possibilities, Limitations and Adverse Effects. Bibliométrie évaluation de la recherche 2015:121–139.
26. 26. Weingart P. Impact of bibliometrics upon the science system: Inadvertent consequences? Scientometrics 2005;62:117–131.
27. 27. Thompson DF, Walker CK. A descriptive and historical review of bibliometrics with applications to medical sciences. Pharmacotherapy 2015;35(6):551–559.